Edwards Lifesciences Co. (NYSE:EW) Shares Sold by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB trimmed its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 7.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 24,755 shares of the medical research company’s stock after selling 2,000 shares during the period. E. Ohman J or Asset Management AB’s holdings in Edwards Lifesciences were worth $1,634,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Crewe Advisors LLC acquired a new stake in shares of Edwards Lifesciences in the 1st quarter worth about $28,000. First Community Trust NA acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter worth about $29,000. Webster Bank N. A. acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter worth about $39,000. Peoples Bank KS acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter worth about $40,000. Finally, Versant Capital Management Inc increased its holdings in shares of Edwards Lifesciences by 206.3% in the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after acquiring an additional 326 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,101,530.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,250 shares of company stock worth $1,099,238. 1.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on EW. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, July 25th. Evercore ISI lowered their target price on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Stifel Nicolaus lowered their target price on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a research note on Thursday, July 25th. JPMorgan Chase & Co. raised their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday. Finally, Truist Financial lowered their target price on shares of Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating on the stock in a research note on Friday. Fifteen analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and an average target price of $75.67.

Edwards Lifesciences Stock Performance

Shares of EW opened at $69.38 on Friday. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a 50-day moving average of $68.08 and a two-hundred day moving average of $78.65. The stock has a market cap of $41.81 billion, a price-to-earnings ratio of 29.91, a PEG ratio of 2.83 and a beta of 1.13. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same period last year, the company posted $0.59 earnings per share. On average, equities research analysts expect that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.